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Objective: TheCenters forMedicare andMedicaid Services (CMS) require high-risk (HR) criteria for carotid artery stenting
(CAS) reimbursement. The impact of these criteria on outcomes after carotid endarterectomy (CEA) and CAS remains
uncertain. Additionally, if these HR criteria are associated with more adverse events after CAS, then existing comparative
effectiveness analysis of CEA vs CASmay be biased.We sought to elucidate this using data from the SVS Vascular Registry.
Methods: We analyzed 10,107 patients undergoing CEA (6370) and CAS (3737), stratiﬁed by CMS HR criteria.
The primary endpoint was composite death, stroke, and myocardial infarction (MI) (major adverse cardiovascular event
[MACE]) at 30 days. We compared baseline characteristics and outcomes using univariate and multivariable analyses.
Results: CAS patients were more likely to have preoperative stroke (26% vs 21%) or transient ischemic attack (23% vs 19%)
than CEA. Although age $80 years was similar, CAS patients were more likely to have all other HR criteria. For CEA,
HR patients had higher MACEs than normal risk in both symptomatic (7.3% vs 4.6%; P < .01) and asymptomatic patients
(5% vs 2.2%; P < .0001). For CAS, HR status was not associated with a signiﬁcant increase in MACE for symptomatic
(9.1% vs 6.2%; P[ .24) or asymptomatic patients (5.4% vs 4.2%; P[ .61). All CAS patients had MACE rates similar to
HR CEA. After multivariable risk adjustment, CAS had higher rates than CEA for MACE (odds ratio [OR], 1.2; 95%
conﬁdence interval [CI], 1.0-1.5), death (OR, 1.5; 95% CI, 1.0-2.2), and stroke (OR, 1.3; 95% CI,1.0-1.7), whereas
there was no difference in MI (OR, 0.8; 95% CI, 0.6-1.3). Among CEA patients, age $80 (OR, 1.4; 95% CI, 1.02-1.8),
congestive heart failure (OR, 1.7; 95% CI, 1.03-2.8), EF <30% (OR, 3.5; 95% CI, 1.6-7.7), angina (OR, 3.9; 95% CI,
1.6-9.9), contralateral occlusion (OR, 3.2; 95% CI, 2.1-4.7), and high anatomic lesion (OR, 2.7; 95% CI, 1.33-5.6)
predicted MACE. Among CAS patients, recent MI (OR, 3.2; 95% CI, 1.5-7.0) was predictive, and radiation (OR, 0.6;
95% CI, 0.4-0.8) and restenosis (OR, 0.5; 95% CI, 0.3-0.96) were protective for MACE.
Conclusions: Although CMS HR criteria can successfully discriminate a group of patients at HR for adverse events after
CEA, certain CMS HR criteria are more important than others. However, CEA appears safer for the majority of patients
with carotid disease. Among patients undergoing CAS, non-HR status may be limited to restenosis and radiation. (J Vasc
Surg 2013;57:1318-24.)Over the last 2 decades, carotid artery stenting (CAS)
has emerged as an alternative to carotid endarterectomy
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8carotid artery stenosis. Meanwhile, subsequent trials have
shown conﬂicting results with failure to meet noninferiority
between the two revascularization procedures in average-
risk patients.1-4 The Centers for Medicare and Medicaid
Services (CMS) have approved reimbursement for CAS in
patients who are at “high risk” for CEA with symptomatic
$70% stenosis unless enrolled in a clinical trial.5 High-risk
(HR) criteria include several medical and anatomic condi-
tions; criteria that many presume are associated with
increased operative risk.
As a result of these HR criteria proposed by CMS,
there may be over representation of HR and/or symptom-
atic patients selected for CAS, which may introduce bias
into the comparisons of CAS and CEA. Additionally, there
is no clear evidence suggesting that the risk with CAS is
lower in these HR patients compared with CEA. The
HR criteria used by CMS were developed years ago based
on outcomes from a randomized trial including mainly
asymptomatic patients6 and several prospective (still
ongoing at that time) CAS registries.7-9 The validity of
Table I. Demographics and clinical characteristics of
10,107 patients undergoing CEA or CAS in SVS VR
CEA
(n ¼ 6370)
CAS
(n ¼ 3737)
P
value
Age, years, mean (range) 70.9 (18-96) 70.9 (34-98) .98
Sex (male) 58.6% 60.4% .08
White - Caucasian 92.8% 91.9% .13
Symptom status 38.0% 41.0% <.01
Preoperative symptoms
Stroke 21.0% 25.5% <.001
TIA 19.1% 23.1% <.001
TMB 5.4% 7.4% <.001
Etiology of lesion <.001
Atherosclerosis 98.2% 68.5%
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authors.10-13 However, the results of these studies cannot
be justiﬁed because they are limited by low numbers of
patients or the inability to adequately stratify patients into
HR groups using only administrative data.
The Vascular Registry (VR) is the largest published
database of CAS in the United States, designed to capture
real-world practices. It, therefore, allows stratiﬁcation of
patients undergoing CAS or CEA by symptom status as
well as the predeﬁned HR criteria of CMS. In this study,
we aimed to assess the validity and the impact of these
HR criteria on 30-day outcomes following CAS and
CEA and to identify patient factors associated with
increased procedural risk.Radiation 0.1% 5.2%
Restenosis 1.3% 24.0%
Diabetes 31.4% 34.0% <.01
Hypertension 84.3% 83.0% .08
Current or past smoker 60.8% 61.3% .65
Coronary artery disease 48.1% 57.8% <.001
Myocardial infarction 16.3% 22.0% <.001
Valvular heart disease 7.9% 6.0% <.001
Cardiac arrhythmia 12.9% 14.4% .03
Congestive heart failure 7.8% 14.1% <.001
COPD 17.7% 20.3% <.01
Chronic renal failure 3.4% 3.8% .28
Peripheral vascular disease 43.7% 37.2% <.001
GI ulcer/bleeding 3.0% 4.8% <.001
Cancer 13.0% 19.8% <.001
Coagulopathy 1.4% 1.1% .20
NYHA scale
Class I or II 95.4% 89.1% <.001
Class III or IV 4.6% 10.9%
CAS, Carotid artery stenting; CEA, carotid endarterectomy; COPD,
chronic obstructive pulmonary disease; GI, gastrointestinal; NYHA, New
York Heart Association; SVS, Society for Vascular Surgery; TIA, transient
ischemic attack; TMB, transient monocular blindness; VR, Vascular
Registry.METHODS
VR data are reported by providers through web-based
electronic data capture. The measurement schedule
includes baseline (preoperative) demographics, medical
history, carotid symptom status, preprocedural diagnostic
imaging and laboratory studies, procedural (CAS or
CEA) information including clinical utility, intraoperative
and predischarge complications, and follow-up information
such as postoperative mortality, stroke, myocardial infarc-
tion (MI), and other morbidity. Speciﬁcally, the VR
includes all individual HR criteria outlined by CMS. The
VR does not use inclusion or exclusion criteria for patient
eligibility and is reliant on site entry of patients in whom
CAS or CEA is performed. All data entered into the VR
are fully compliant with the Health Insurance Portability
and Accountability Act regulations and are auditable. All
data reports and analyses performed include only de-
identiﬁed and aggregated data. New England Research
Institutes, Inc (Watertown, Mass) maintains the online
database and funding for the administration and database
management of the VR has been provided by the Society
for Vascular Surgery.
Outcomes. The primary endpoint was a major adverse
cardiovascular event (MACE) diagnosed within 30 days
of treatment, deﬁned as a composite of death, stroke, and
MI. Secondary outcomes were combined stroke and death,
death, stroke, and MI at 30 days following CAS and CEA.
Stroke is deﬁned as any nonconvulsive, focal neurologic
deﬁcit of abrupt onset persisting more than 24 hours.
The ischemic event must correspond to a vascular territory.
An MI is classiﬁed as either Q wave MI in which one of the
following criteria is required: (1) chest pain or other acute
symptoms consistent with myocardial ischemia and new
pathologic Q waves in two or more contiguous electro-
cardiogram leads, or (2) new pathologic Q waves in two or
more contiguous electrocardiogram leads and elevation of
cardiac enzymes; or non-Q wave MI, deﬁned as CK
ratio >2, and CK-MB >1 in the absence of new, patho-
logic Q waves. Analysis of 30-day outcomes was based on
only those patients who had at least a 30-day post-
procedure visit or who experienced a MACE within 30
days of treatment.Statistical methods. Tests of statistical signiﬁcance
were conducted with c2 or Fisher exact tests for categorical
variables and two-tailed t-test for continuous variable age.
Descriptive statistics are listed as percent (frequency) for
categorical variables and mean (range) for continuous
variable age. Subset analyses were performed using the c2
or Fisher exact test, as necessary, for discrete/categorical
data. The event rates are calculated per-patient. Unad-
justed and adjusted ORs were used to compare the primary
outcomes across treatment groups. ORs were adjusted for
symptomatic status and HR status in the overall compar-
ison of CEA and CAS. Differences were considered
signiﬁcant if P < .05. All statistical analyses were performed
by New England Research Institutes, Inc using SAS
Statistical Software (SAS Institute, Cary, NC).RESULTS
Data collected in the VR from November 2001 to
September 2011 from 81 institutions (community-based,
university-based, private practice, and nonuniversity teach-
ing hospitals) were analyzed; 10,107 patients who under-
went CEA (n ¼ 6370; 37.5% symptomatic) and CAS
Table II. CMS qualifying HR factors
CEA
(n ¼ 6370)
CAS
(n ¼ 3737)
P
value
Age $80 years 19.3% 20.7% .10
NYHA CHF class III/IV 3.5% 10.4% <.001
LVEF <30% 0.9% 4.1% <.001
Unstable angina 0.6% 3.6% <.001
Recent MI (within 30 days) 0.5% 1.2% <.001
Restenosis 2.5% 29.5% <.001
Radical neck dissection 0.1% 4.0% <.001
Contralateral occlusion 4.3% 13.4% <.001
Prior radiation to neck 0.3% 8.4% <.001
Contralateral laryngeal
nerve injury
0.1% 0.9% <.001
High anatomic lesion 1.2% 9.4% <.001
At least one HR factor 37.0% 90.5% <.001
CAS, Carotid artery stenting; CEA, carotid endarterectomy; CHF,
congestive heart failure; CMS, Centers for Medicare and Medicaid Services;
HR, high risk; LVEF, left ventricular ejection fraction; MI, myocardial
infarction; NYHA, New York Heart Association.
Table III. Thirty-day event rates for symptomatic
patients undergoing CEA and CAS stratiﬁed by risk
group
CEA patients
P valueHR (n ¼ 936) Non-HR (n ¼ 1470)
MACE 7.3% 4.6% <.01
Stroke, death 6.4% 3.9% <.01
Mortality 1.8% 0.6% <.01
Stroke 4.9% 3.5% .09
MI 1.4% 1.1% .57
CAS patients
P valueHR (n ¼ 1538) Non-HR (n ¼ 162)
MACE 9.1% 6.2% .25
Stroke, death 7.9% 4.9% .21
Mortality 2.4% 1.9% 1.00
Stroke 6.7% 3.7% .18
MI 1.4% 1.2% 1.00
CAS, Carotid artery stenting; CEA, carotid endarterectomy; HR, high risk;
MACE, major adverse cardiovascular events; MI, myocardial infarction.
Table IV. Thirty-day event rates for asymptomatic
patients undergoing CEA and CAS stratiﬁed by risk
group
CEA patients
P valueHR (n ¼ 1418) Non-HR (n ¼ 2546)
MACE 5.0% 2.2% <.001
Stroke, death 3.7% 1.4% <.001
Mortality 1.3% 0.5% <.01
Stroke 2.7% 1.1% <.001
MI 1.6% 1.1% .30
CAS patients
P valueHR (n ¼ 1844) Non-HR (n ¼ 193)
MACE 5.4% 4.2% .61
Stroke, death 4.8% 3.6% .59
Mortality 1.7% 1.6% 1.00
Stroke 3.4% 2.6% .68
MI 1.1% 1.0% 1.00
CAS, Carotid artery stenting; CEA, carotid endarterectomy; HR, high risk;
MACE, major adverse cardiovascular events; MI, myocardial infarction.
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outcomes were identiﬁed. The majority of the procedures
(71% CAS; 93% CEA) were performed by vascular
surgeons. Baseline demographics, patient characteristics,
CMS HR status, and individual HR factors are presented
in Tables I and II. Mean age was 71 years, and approxi-
mately 59% were male and 92% were white. CAS patients
were more likely to have a preoperative stroke (25.5% vs
21.0% CEA; P # .001) or transient ischemic attack
(23.1% vs 19.1% CEA; P # .001) compared with CEA
patients. CAS patients also had a signiﬁcantly higher prev-
alence of cardiac comorbidities (coronary artery disease
[57.8% vs 48.1%], MI [22% vs 16.3%], chronic heart failure
[14.1% vs 7.8%]), and nonatherosclerotic disease (recurrent
or radiation-induced stenosis [31.5% vs 1.8%]). All indi-
vidual CMS qualifying HR factors were more prevalent in
CAS patients, except for age $80 (19.3% CAS vs 20.7%
CEA; P ¼ NS). Only 37% of CEA patients met any of
the HR factors compared with 90.5% of CAS patients
(P <.001).
CEA outcomes. In symptomatic patients, the 30-day
rate of MACE was 7.3% in HR patients vs 4.6%
(P ¼ .008) in non-HR patients. Combined stroke/death
and death rates were signiﬁcantly higher in HR patients
compared with non-HR patients (6.4% vs 3.9%; P ¼ .006;
and 1.8% vs 0.6%; P ¼ .008, respectively). Stroke alone did
not show signiﬁcant differences between HR and non-HR
symptomatic patients (4.9% vs 3.5%; P ¼ .09). The rate of
MI was similar between HR and non-HR patients (1.4% vs
1.1%; P ¼ .57) (Table III). In asymptomatic patients, the
30-day rate of MACE was 5.0% in HR patients vs 2.2% in
non-HR patients (P < .001). Combined stroke/death,
death, and stroke rates were all signiﬁcantly higher in HR
patients compared with non-HR patients. There was no
difference in the rate of MI between HR and non-HR
asymptomatic patients (1.6% vs 1.1%; P ¼ .30) (Table IV).
In univariate analysis, patients with contralateral occlu-
sion had signiﬁcantly higher risks of MACE (symptomatic,16.1%; asymptomatic, 8.8%), stroke/death (symptomatic,
16.1%; asymptomatic, 7.2%), death (symptomatic and
asymptomatic 2.2%), and stroke (symptomatic, 15.1%;
asymptomatic, 5.0%) compared with patients without
contralateral occlusion. A multivariable model showed
that symptomatic status, age $80, CHF class III/IV, left
ventricular ejection fraction <30%, angina, contralateral
occlusion and high anatomic lesion were independent
predictors for MACE (Table V). The same factors were
identiﬁed as predictors for stroke/death with the exception
of age $80. CHF, angina, restenosis, and contralateral
occlusion were risk factors for death. For stroke alone,
Table V. Predictors for 30-day outcomes of CEA
Risk factors
MACE Stroke/death Stroke Death MI
OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Symptomatic 1.8 1.4-2.4 2.3 1.7-3.1 2.5 1.8-3.5 - - - -
Age $80 years 1.4 1.0-1.8 - - - - - - - -
CHF class (III/IV) 1.7 1.0-2.8 1.8 1.0-3.2 - - 3.5 1.5-7.8 - -
LVEF <30% 3.5 1.6-7.7 3.2 1.3-7.6 - - - - - -
Angina 3.9 1.6-9.9 3.2 1.1-9.6 - - 5.9 1.6-21.4 6.8 2.0-22.5
Contralateral occlusion 3.2 2.1-4.7 3.7 2.4-5.8 4.1 2.6-6.6 2.5 1.0-5.9 - -
High anatomic lesion 2.7 1.3-5.6 3.0 1.4-6.5 3.4 1.5-7.6 - - - -
Restenosis - - - - - - 3.6 1.4-9.3 - -
CEA, Carotid endarterectomy; CHF, congestive heart failure; CI, conﬁdence interval; LVEF, left ventricular ejection fraction; MACE, major adverse
cardiovascular event; MI, myocardial infarction; OR, odds ratio.
Table VI. Predictors for 30-day outcomes of CAS
Risk factors
MACE Stroke/death Stroke Death MI
OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Symptomatic 2.0 1.5-2.6 1.6 1.2-2.1 2.0 1.5-2.7 - - - -
Age $80 years - - - - 1.5 1.1-2.1 - - 2.1 1.1-3.8
Recent MI 3.2 1.5-7.0 4.0 2.0-8.3 - - 8.0 3.4-18.9 - -
Angina - - - - - - 2.4 1.1-5.6 - -
Contralateral occlusion - - - - - - 1.9 1.1-3.4 - -
Restenosis 0.6 0.4-0.8 0.6 0.5-0.9 - - - - - -
Prior radiation to neck 0.5 0.3-0.9 0.5 0.3-0.9 - - - - - -
CAS, Carotid artery stenting; CI, conﬁdence interval; MACE, major adverse cardiovascular event; MI, myocardial infarction; OR, odds ratio.
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anatomic lesion were predictive. Angina was the only risk
factor identiﬁed for MI.
CAS outcomes. In both symptomatic and asymptom-
atic CAS patients, no signiﬁcant difference was detected in
MACE between HR and non-HR patients (9.1% vs 6.2%;
P ¼ .25 symptomatic; 5.4% vs 4.2%; P ¼ .6 asymptomatic)
(Tables III and IV). Stroke/death, mortality, stroke, and
MI rates were similar in both groups for both symptomatic
and asymptomatic patients.
In a multivariable model, symptom status (odds ratio
[OR], 1.6; 95% conﬁdence interval [CI], 1.3-2.2) and
recent MI (OR, 3.4; 95% CI, 1.7-7.0) were independent
predictors for MACE, whereas restenosis (MACE rate,
3.5%, OR, 0.6; 95% CI, 0.4-0.8) and previous cervical radi-
ation therapy (MACE rate, 4.6%; OR, 0.4; 95% CI, 0.2-0.8)
were protective (Table VI). The same predictors were iden-
tiﬁed for combined stroke/death. Angina (OR, 2.4; 95%
CI, 1.1-5.6), previous MI (OR, 8.0; 95% CI, 3.4-18.9),
and contralateral occlusion (OR, 1.9; 95% CI, 1.1-3.4)
were risk factors for mortality. Independent predictors for
stroke alone were symptom status and age $80 years. Age
$80 was the only predictor for MI (OR, 2.1; 95% CI,
1.1-3.8).
Anatomic HR factors. In symptomatic patients with
contralateral occlusion, the 30-day MACE rate was 16.1%
after CEA and 9.3% after CAS (P ¼ .13). In asymptomatic
patients, MACE rates were 8.8% after CEA vs 6.9% afterCAS (P ¼ .58). Risk for MACE in patients with symp-
tomatic restenosis was 7.9% after CEA vs 6.7% (P ¼ .79)
after CAS and 7.1% vs 3.5% (P ¼ .10) in asymptomatic
patients. Patients with prior neck radiation undergoing CAS
(n¼ 315) had a MACE risk of 4.5% (symptomatic patients)
and 2.5% (asymptomatic patients). Only 19 patients with
prior neck irradiation had CEA without any adverse events.
For patients with a high anatomic lesion (C2 or higher),
symptomatic patients had a risk for MACE of 11.9% after
CEA vs 13.2% after CAS (P ¼ 1.0). In asymptomatic
patients, theMACE rate was 12.2% after CEA vs 4.52% after
CAS (P ¼ .13).
CAS vs CEA outcome. No signiﬁcant differences in
MACE were identiﬁed between CAS and CEA within
the strata of the non-HR and HR groups. Symptomatic
HR patients had 9.1% MACE risk following CAS vs 7.3%
after CEA (OR, 1.3; 95% CI, 0.95-1.73; P ¼ .11). MACE
risk in asymptomatic HR patients was 5.4% after CAS vs
5.0% after CEA (OR, 1.1; 95% CI, 0.79-1.47; P ¼ .65). In
the non-HR group, symptomatic patients undergoing CAS
had a MACE risk of 6.2% vs 4.6% in patients undergoing
CEA (OR, 1.4; 95% CI, 0.69-2.69; P ¼ .38). For
asymptomatic non-HR patients, the MACE risk was 4.2%
after CAS vs 2.2% after CEA (OR, 1.92; 95% CI, 0.90-
4.09; P ¼ .09). In unadjusted models assessing outcome
across treatment groups, CAS patients had higher ORs for
MACE (OR, 1.7; 95% CI, 1.4-2.0), combined stroke and
death (OR, 1.9; 95% CI, 1.6-2.3), mortality (OR, 2.3; 95%
Table VII. Thirty-day outcome of CAS vs CEA,
unadjusted and adjusted for HR and symptomatic
patients
Unadjusted CAS vs
CEA
Adjusted CAS vs
CEA
OR 95% CI P value OR 95% CI P value
MACE 1.7 1.4-2.0 <.001 1.2 1.0-1.5 .04
Stroke, death 1.9 1.6-2.3 <.001 1.3 1.1-1.7 .01
Death 2.3 1.6-3.2 <.001 1.5 1.0-2.2 .04
Stroke 1.9 1.5-2.4 <.001 1.4 1.1-1.7 .02
MI 0.9 0.7-1.4 .91 0.9 0.6-1.3 .46
CAS, Carotid artery stenting; CEA, carotid endarterectomy; CI, conﬁdence
interval; HR, high risk; MACE, major adverse cardiovascular event; MI,
myocardial infarction; OR, odds ratio.
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not for MI (OR, 0.9; 95% CI, 0.7-1.4). After adjusting for
symptom and HR status, CAS patients had still higher ORs
for MACE (OR, 1.2; 95% CI, 1.0-1.5), mortality (OR,
1.5; 95% CI, 1.0-2.2), and stroke (OR, 1.4; 95% CI, 1.0-
1.7), whereas there was no difference in stroke/death and
MI. (Table VII).
DISCUSSION
Patients with symptomatic or asymptomatic severe
carotid stenosis and HR status have an increased risk for
MACE following CEA compared with non-HR patients
undergoing CEA. Of the CMS HR criteria, age $80,
CHF, angina, contralateral occlusion, and high anatomic
lesion predict MACE after CEA. For CAS, 30-day
outcomes between HR and non-HR patients were similar.
Prior MI predicted MACE after CAS, whereas previous
radiation and restenosis proved to be protective conditions.
By comparing CAS and CEA after adjusting for symptoms
and HR status, CAS patients had signiﬁcantly higher rates
than CEA for MACE, combined stroke/death, mortality,
and stroke, whereas there was no difference in MI.
Our results emphasize that some, but not all, CMS HR
criteria identify patients at increased risk for MACE after
CEA. However, these patients do not per se seem to
beneﬁt from CAS. CMS reimbursement for CAS covers
HR symptomatic patients, as long as stenting is performed
using FDA-approved systems with embolic-protection
devices and at CMS-approved facilities. This policy was
mainly based on favorable endovascular results of the
Stenting and Angioplasty with Protection in Patients at
High Risk for Endarterectomy (SAPPHIRE) trial,
designed to compare CAS vs CEA in an HR popula-
tion.6,14 The applicability of the results was however ques-
tioned by several others. In SAPPHIRE, the 30-day stroke,
death, and MI rates in the CEA arm were as high as 9.8%
(vs 4.8% CAS; P ¼ .09). The MI rate of 6.6% strongly
inﬂuenced this combined endpoint. Also, approximately
70% of the study population was asymptomatic. Outcomes
of our VR real-world data looking at the same HR popula-
tion consequently do not compare with the SAPPHIREtrial, with a MACE rate of 5.0% (MI rate, 1.6%) after
CEA in asymptomatic patients and 7.3% in symptomatic
patients. Noteworthy, the primary end point in
SAPPHIRE did not differ signiﬁcantly in symptomatic
patients at 30 days and at 1 year (16.8% CAS vs 16.5%
CEA; P ¼ .95), one of the major reimbursement criteria
from CMS.
Several other studies have retrospectively sought to
evaluate medical,10,13 anatomical,15-17 or a combination
of HR criteria11,12,18,19 outlined by CMS. Most of these
studies analyzed risk factors against a non-HR group in
only one treatment arm (CAS or CEA). Our prior anal-
ysis10 using the Nationwide Inpatient Sample identiﬁed
signiﬁcantly lower stroke/death rates after CEA compared
with CAS with a stratiﬁed analysis by symptom status and
HR status, questioning the validity of the HR criteria. In
that analysis, medical HR status was associated with
worse outcome (stroke/death, mortality) following CEA
compared with non-HR patients undergoing CEA.
Outcomes with CAS, however, were not improved in these
HR patients (combined stroke/death CAS vs CEA in
symptomatic patients: 14.4% vs 6.9%; P < .001). However,
anatomic HR could not be determined and medical HR
could not be precisely quantiﬁed because of the limitations
of administrative data. Additionally, outcome events other
than death may not be reliably documented with adminis-
trative data.
We undertook the current analysis to perform a thor-
ough identiﬁcation of HR factors and better discrimination
of pre- and postoperative outcomes. We found that recent
angina was a predictor for all major outcomes after CEA
except for stroke alone and also a predictor for death after
CAS. We also found that those patients aged $80 years
had an increased risk for MACE after CEA and for stroke
and MI after CAS. A differential effect of advancing age
on outcome was also observed in the Carotid Revasculari-
zation Endarterectomy vs Stenting Trial (CREST) lead in
and the randomized trial, where older patients had signiﬁ-
cantly better outcomes after CEA and younger patients had
a nonsigniﬁcant trend toward better outcomes after
CAS.20-22
Considering anatomic HR factors, we found that
patients with contralateral occlusion were at HR for ad-
verse outcomes following CEA and CAS. Controversy
regarding the beneﬁt of CEA exists in patients with contra-
lateral occlusion, with some studies reporting similar
outcomes after CEA,17,23 whereas others show increased
risk of adverse events.24,25 However, little data exist to
evaluate the impact on CAS outcomes.26 Our data suggest
that the risk for adverse outcome after both CEA and CAS
was increased in patients with contralateral occlusion, in
both symptomatic and asymptomatic patients. We were
not able to assess shunt use during CEA, which might
impact perioperative outcome. For patients with restenosis,
this was not true. With an OR of 3.6 (95% CI, 1.4-9.3),
restenosis was predictive for death after CEA, but proved
to be a protective condition for MACE and stroke/death
after CAS. However, MACE rates were similarly high
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but for asymptomatic patients, the MACE rate with CAS
was one-half that of CEA (3.5% vs 7.1%; P ¼ NS). This
expands the evidence of a prior report of the VR, were
no differences in stroke/death/MI rate between CAS
patients with atherosclerotic disease compared with nona-
therosclerotic disease (eg, restenosis and prior radiation
therapy) were identiﬁed.15 These ﬁndings suggest that
asymptomatic patients with restenosis or prior radiation
therapy might be considered as the only “low” risk group
in CAS. Differences in histology may explain this observa-
tion because intimal hyperplasia and radiation-induced pla-
que have been shown to be more stable compared with
atherosclerotic plaque.27,28 Additionally, patients with
high anatomic lesions suffered from high MACE risks after
both procedures (>10% in symptomatic patients), far
beyond the accepted complication rates after carotid revas-
cularization and, thus, questioning the beneﬁt of revascu-
larization over medical treatment in these patients. No
such trials exist today, and accepted rates are, however,
based on trials in which these patients were speciﬁcally
excluded, such as CREST.29
Results of the CREST trial showed that both symp-
tomatic and asymptomatic patients had equal low risks after
CAS and CEA for combined stroke/death/MI.22 Stroke
rates alone were lower following CEA, whereas an
increased risk for MI was seen compared with CAS. Symp-
tomatic patients had lower stroke and death rates with
CEA compared with CAS.30 As stated above, most HR
criteria outlined by the CMS (except for age $80 years
and contralateral occlusion) were exclusion criteria in this
trial. The study also required that interventionalists have
documented prior performance of at least 35 CAS proce-
dures, emphasizing that CAS might be a safe procedure
under speciﬁc conditions in selected patients treated by
selected physicians. Unadjusted data from a regional
quality improvement registry (Vascular Study Group of
New England) showed increased in-hospital risk for
stroke/death/MI in symptomatic patients undergoing
CAS (5.8%) compared with CEA (2.7%) but equal results
in asymptomatic patients.31 In the real-world data from
the VR, the vast majority (90.5%) of the CAS patients
meet CMS HR criteria and had more comorbid conditions
than CEA patients where only 37% were HR, making
unadjusted comparison difﬁcult to interpret and likely
biased.
This study has several limitations. Self-reporting bias by
treating physicians and institutions is inherent to any
registry-based study and the potential effect of reporting
bias within the VR has been investigated and discussed.
Given that 90% of CAS patients were HR, there were a rela-
tively small number of patients in the non-HR group avail-
able for stratiﬁed analysis. It is possible that a type II error
prevented ﬁnding a signiﬁcant difference in subgroup
comparisons stratiﬁed by symptom status and non-HR
status. It is also possible that some of the patients consid-
ered non-HR were in fact HR and were mislabeled.
Given that CMS reimbursement and site approval forperformance of CAS in Medicare patients is dependent
upon this documentation, we believe that this is unlikely.
Non-HR patients may be entered into clinical trials and
have CMS reimbursement. Because the VR data are
capturing real-world data, it is reliant on site entry of
patients without predeﬁned exclusion or inclusion criteria.
Therefore, differences in patient selection may have
occurred for both CAS and CEA. Lastly, the combined
outcome of MACE is ﬂawed in that it equates death,
stroke, and MI. Although there has been considerable
debate about the relative importance of stroke vs MI,32-34
we do not think that this impacts our ﬁndings, as we had
similar ﬁndings using the stroke/death outcome that had
previously been considered the standard.
In conclusion, we ﬁnd that certain CMS HR criteria
are associated with adverse outcomes after CEA. However,
outcomes in HR patients are not improved after CAS, and
patients treated with CEA fare better than CAS after
adjustment for symptom status and HR status. Therefore,
our study ﬁnds little advantage for CAS over CEA in
patients at HR for perioperative complications and suggests
that the strongest advantage of CAS over CEA lies in
patients with restenosis or prior neck radiation, compared
with those patients with HR medical conditions.AUTHOR CONTRIBUTIONS
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